The Patent Finder

Humanigen, Inc.

11 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Kalobios Pharmaceuticals, Inc. (to 2017)

2
Ending by 2030
Apr 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 2 to 13, 2026 · next Dec 2
  • 1 fee due Feb 18, 2027
    The maintenance fee for Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow (US 9,109,032) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
  • 1 fee due Sep 22, 2027
    The maintenance fee for Antibodies to EphA3 (US 9,290,571) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,168,183Antibodies to granulocyte-macrophage colony-stimulating factor
In force
 · USPTO record
In forceUSPTO record
US 9,017,674Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
In force
 · Low confidence
In forceLow confidence
US 9,290,571Antibodies to EphA3
In force
 · USPTO record
In forceUSPTO record
US 8,834,870Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
In force
 · USPTO record
In forceUSPTO record
US 9,045,539Anti-EMR1 antibodies
In force
 · USPTO record
In forceUSPTO record
US 9,109,032Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
In force
 · USPTO record
In forceUSPTO record
US 10,870,703Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
In force
 · USPTO record
In forceUSPTO record
US 10,899,831Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
In force
 · USPTO record
In forceUSPTO record
US 10,927,168Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
In force
 · USPTO record
In forceUSPTO record
US 11,130,805Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
In force
 · USPTO record
In forceUSPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 1 patent in force now held by others · 3 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 10 no status recorded

Showing 1 to 10 of 14, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/283,196Materials and Methods for Treating CancerMar 15, 2022Pending
18/280,642Mar 4, 2022No status recorded
17/378,629Jul 16, 2021No status recorded
17/306,884May 3, 2021No status recorded
17/234,779Apr 19, 2021No status recorded
17/216,660Mar 29, 2021No status recorded
17/209,160Materials and Methods for Treating CancerMar 22, 2021Abandoned
17/909,377Mar 8, 2021No status recorded
17/160,325Jan 27, 2021No status recorded
17/151,154Jan 16, 2021No status recorded
10 of 14 applications shown.
Pro members see all 14 published applications.
Pro members: see all 14 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited